Short Summary
Olympus and other camera makers settled their IPR dispute with Optimum Imaging Technologies and jointly moved to terminate the proceeding. The Board has not decided any merits, and the parties cite statutory authority for termination.
Detailed Summary
In IPR2024-01220 concerning U.S. Patent No. 10,873,685, Olympus Corporation, OM Digital Solutions, Fujifilm, Fujifilm North America, Nikon, and Panasonic entered into settlement agreements with patent owner Optimum Imaging Technologies LLC. Citing 35 U.S.C. §317 and relevant CFR provisions, the parties jointly filed a motion to terminate the inter partes review, arguing that settlement resolves all disputes and that the Board has not yet ruled on the merits. The motion emphasizes public‑policy considerations favoring settlement and seeks full termination of the IPR.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Olympus Corporation et al. vs Optimum Imaging Technologies LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Abbott LaboratoriesvsNewtonoid Technologies, LLC
Abbott Laboratories filed a Petition challenging Newtonoid Technologies' patent claims based on obviousness. The petitioner argues that combining known technologies, such as dynamic barcodes and environmental monitoring, renders the claims unpatentable over multiple prior art references. This challenge targets 18 specific claims related to stimuli-responsive labels.
Apple Inc.vsProxense, LLC
Apple has filed an IPR petition challenging all 20 claims of Proxense’s ’188 patent, asserting obviousness over multiple prior‑art references and arguing that discretionary denial is unwarranted.
Shenzhen Tuozhu Technology Co., Ltd. et al.vsStratasys, Inc. et al.
Shenzhen Tuozhu Technology seeks denial of Stratasys' Director Review request, arguing the PTAB’s referral decision correctly applied the Fintiv factors and that a broad stipulation eliminates any need for duplicate litigation. The petition emphasizes that incorporation‑by‑reference arguments are irrelevant to institution.
Merck Sharp & Dohme LLCvsHalozyme, Inc. et al.
Merck has filed a post‑grant review petition challenging Halozyme’s U.S. Patent 12,077,791 covering modified PH20 hyaluronidase proteins. The petition asserts that the claims are overly broad and lack both written description and enablement under 35 U.S.C. §112(a). Merck seeks institution of the proceeding and cancellation of all claims.
Samsung Electronics Co., Ltd. et al.vsZophonos Inc.
Samsung has filed an IPR petition challenging 13 claims of Zophonos’s hearing‑protection patent, asserting that the claims are obvious over a combination of prior‑art references covering earpieces, wireless communication, and audio‑control interfaces.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.